Login
Companies $ROIV
$39.11 +$0.50 (1.3%) After hours
Roivant Sciences Ltd. logo

Roivant Sciences Ltd.

roivant.com

What Do They Do?

Develops medicines for patients with autoimmune diseases and pulmonary hypertension through subsidiaries, and incubates discovery-stage and healthcare technology companies.

How Do They Make Money?

Roivant earns money by licensing intellectual property, receiving payments tied to development milestones and royalties when licensees make sales, and providing technology through subscription and service fees.

FY2026 revenue

Who Are Their Customers?

Drug licensees pay Roivant for intellectual-property rights; technology customers use subscription and service offerings. U.S. healthcare professionals can prescribe LISRAYA, with prescriptions submitted through its enrollment site.

Do Revenues Turn Into Profits?

No. It lost $299.8M in FY2026.

Operating income, FY2026
−6236% of revenue
▲ +49% (Loss) vs FY2025 (−$1B, −3453%)
Net income, FY2026
−3629% of revenue
▼ −74% (Loss) vs FY2025 (−$172M, −592%)
Free cash flow, FY2026
−9184% of revenue
▲ +10% (Loss) vs FY2025 (−$844.1M, −2905%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q2 FY2026, the three months to Sep 30, 2026
Revenue
▲ +2136%
vs $1.6M in Q2 FY2025
Net income
▼ −69% (Loss)
vs −$113.5M in Q2 FY2025
  • Aug 27, 2026 FDA approves LISRAYA for adults with dermatomyositis LISRAYA became available immediately in the U.S.

Shrinking. Revenue fell 85% in 4 years, from $55.3M in FY2022 to $8.3M in FY2026, about 38% a year.

From marketed product to development pipeline The older report included a commercially launched medicine alongside its drug candidates; the latest report describes Roivant's pipeline and says it had no products approved for commercial sale.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support